<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347495">
  <stage>Registered</stage>
  <submitdate>23/02/2012</submitdate>
  <approvaldate>29/02/2012</approvaldate>
  <actrnumber>ACTRN12612000252819</actrnumber>
  <trial_identification>
    <studytitle>A Randomised Controlled trial of intravenous immunoglobulin (IVIg) compared with pulse methyl-prednisolone for the treatment of chronic active antibody mediated rejection</studytitle>
    <scientifictitle>A Randomised Controlled trial of intravenous immunoglobulin (IVIg) compared with pulse methyl-prednisolone in Renal Transplant recipients with chronic active antibody mediated rejection to determine histological change on biopsy</scientifictitle>
    <utrn />
    <trialacronym>VIPAR</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>chronic active antibody mediated rejection of the renal allograft</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment with intravenous methylprednisolone, 3 doses at 250mg/dose over 3 consecutive days and intravenous immunoglobulin (1gm/kg), 3 doses once per month over 3 months. The above is then repeated after 3 months if there is ongoing active rejection on follow-up biopsy. A further 2 biopsies are preformed at 6 and 12 months. Biopsies entail a local anaesthetic to the skin over the kidney and then passing a 14 gauge needle into the transplant kidney to remove a tiny core of tissue. The participant must stay in a day procedude facility for 4 hours after the procedure to monitor for complications such as bleeding. These are diagnostic procedure and are not therapeutic.</interventions>
    <comparator>Treatment with intravenous methylprednisolone, 3 doses at 250mg/dose over 3 consecutive days. The above is then repeated after 3 months if there is ongoing active rejection on follow-up biopsy. A further 2 biopsies are preformed at 6 and 12 months.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>chronic allograft damage index (CADI score)</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>change in renal function (GFR)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>graft loss as determined by a return to dialysis or death.</outcome>
      <timepoint>during follow-up period (indefinite)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>patient survival as assessed by patients vital status.</outcome>
      <timepoint>during follow-up period (indefinite)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in proteinuria as assessed by serial (3 monthly)urine samples analysed for protein to creatinine ratios.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>change in donor specific antibody mean fluorescence index</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Renal transplant recipient
&gt;6 months post-transplant

Biopsy evidence of cAMR defined by
  - Activity - Peritubular capillaritis &gt;10%
  - Chronic Changes - Transplant glomerulopathy or IFTA or peritubular capillary basement membrane multi-lamellation or fibrous intimal thickening of arteries.

Evidence of antibody activity
  - DSAb and/or
  - Positive C4d staining</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Damage to extensive
 - IFTA &gt;50%
 - eGFR &lt;25ml/min
 - proteinuria &gt;3gm/day
Too aggressive
 - Banff PTC score =3 
 - Vascular rejection 
 - CMR
Concomitant biopsy findings
 - Recurrent or de novo GN
 - Diabetic nephropathy
 - Interstitial nephritis
 - BKVAN</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/03/2012</anticipatedstartdate>
    <actualstartdate>21/09/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr William Mulley</primarysponsorname>
    <primarysponsoraddress>Department of Nephrology
Monash Medical Centre
246 Clayton Rd
Clayton
Vic 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial seeks to determine if one of 2 currently used treatment regimens for chronic antibody mediated rejection of the renal allograft is superior to the other in terms of preventing chronic damage. The 2 arms include conversion to tacrolimus, mycophenolate and oral prednisolone with pulse methylprednisolone. Arm one has the addition of 3x monthly doses of IVIg. A second round of therapy will be offered if at 3 months a renal biopsy shows ongoing rejection.
Chronic damage will be assessed by chronic allograft damage index scores at 12 months.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health Human Research Ethics Committee B</ethicname>
      <ethicaddress>Research Directorate
Southern Health
Monash Medical Centre
Locked Bag 29
Clayton South
Vic 3169</ethicaddress>
      <ethicapprovaldate>22/02/2012</ethicapprovaldate>
      <hrec>12036B</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>William Mulley</name>
      <address>Department of Nephrology
Monash Medical Centre
246 Clayton Rd
Clayton
Vic 3168</address>
      <phone>61 3 9594 3518</phone>
      <fax />
      <email>bill.mulley@monashhealth.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>William Mulley</name>
      <address>Department of Nephrology
Monash Medical Centre
246 Clayton Rd
Clayton
Vic 3168</address>
      <phone>61 3 9594 3518</phone>
      <fax />
      <email>bill.mulley@southernhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>William Mulley</name>
      <address>Department of Nephrology
Monash Health
246 Clayton Rd
Clayton 3168
Victoria
</address>
      <phone>61 3 9594 3518</phone>
      <fax />
      <email>bill.mulley@monashhealth.org</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>